Hormonal and metabolic effects of diet and physical exercise in overweight/obese women with polycystic ovary syndrome. by Nybacka, Åsa
From the DEPARTMENT OF WOMEN’S AND CHILDREN’S 
HEALTH 
Division of Obstetrics and Gynecology 
Karolinska Institutet, Stockholm, Sweden 
HORMONAL	AND	METABOLIC	EFFECTS	OF		
DIET	AND	PHYSICAL	EXERCISE	IN		
OVERWEIGHT/OBESE	WOMEN	WITH	POLYCYSTIC	OVARY	
SYNDROME		
	
	  
Åsa Nybacka 
 
Stockholm 2019 
 
 All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Exakta 
© Åsa Nybacka, 2019 
ISBN 978-91-7831-017-3 
HORMONAl	AND	METABOLIC	EFFECTS	OF	DIET	AND	
PHYSICAL	EXERCISE	IN	OVERWEIGHT/OBESE	WOMEN	WITH	
POLYCYSTIC	OVARY	SYNDROME	 	
 
THESIS FOR LICENTIATE DEGREE 
By 
Åsa Nybacka 
Principal Supervisor: 
Professor Angelica Lindén Hirschberg 
Karolinska Institutet 
Department of Women’s and Children’s Health 
Division of Obstetrics and Gynecology 
 
Co-supervisor: 
Professor Per M Hellström 
Uppsala University 
Department of Medical Sciences 
Gastroenterology Unit 
 
Examination Board: 
Ass professor Anna-Clara Spetz Holm 
Linköping University 
Department of Clinical and Experimental 
Medicine  
Division of Children's and Women's Health  
 
Professor Tommy Cederholm 
Uppsala University 
Department of Public Health and Caring Sciences 
Division of Clinical Nutrition and Metabolism 
 
Ass professor Lars Hagenäs 
Karolinska Institutet 
Department of Women’s and Children’s Health 
Division of Pediatric endocrinology 

  
 
 
ABSTRACT 
Background: Overweight/obese women with polycystic ovary syndrome (PCOS) often 
have hormonal problems characterized by irregular menses and decreased fertility. In 
addition, the overweight/obese women carry metabolic disturbances with a long-term risk 
of type 2 diabetes and cardiovascular disease. 
Aims: The purpose of the study was to imply an individualized intervention employing 
either diet, exercise or the combination of both, to disentangle which of these treatment 
options that show the most favorable outcome in terms of hormone levels, menstrual 
regularity and ovarian function. Furthermore, effects on metabolic outcome variables were 
evaluated. 
Methods: In a randomized comparative study, 57 overweight/obese PCOS women were 
assigned to an intervention program with either diet, exercise or the combination of both for 
a period of four months. The goal was to reduce the food intake by 600 kcal and increase 
the physical activity to 45–60 minutes of moderate to vigorous training 2–3 times per week. 
All patients were monthly monitored for adherence to the intervention program by either a 
dietician or physiotherapist, and subjected to a long-term evaluation after 12 months or 
more. Menstrual bleedings were recorded and ovarian parameters evaluated by ultrasound. 
The specific endocrine measurements consisted of changes in estradiol, progesterone, 17-
OH-progesterone, luteinizing hormone, follicle stimulating hormone, sex hormone binding 
globulin, and dehydroepiandrosterone, as well as fasting glucose and oral glucose tolerance 
test, insulin, insulin-like growth factor-I, IGF-I binding protein 1 and serum levels of total 
cholesterol, high density lipoprotein, low density lipoprotein (LDL), triglycerides and C-
reactive protein. Calculations were made for Homeostasis Model of Assessment (HOMA) 
index and free androgen index. Dual-energy X-ray absorptiometry was used to evaluate 
body composition. The values are presented as means ± standard deviation, or 95% 
confidence interval, or as medians with interquartile range. The data was evaluated using 
intention to treat or per protocol approach.  
Results: There were no differences between the three groups at baseline. None of the 
participants were diabetic, but the majority displayed a HOMA index exceeding 3, 
indicating insulin resistance. The most important dietary change during the study was a 
reduced energy intake with more fiber, and less saturated fat and trans fatty acids based on 
the Swedish Nutritional Recommendations Objectified. Physically activity increased 
significantly in the exercise group as assessed by the number of steps per day. The 
summarized effects of the lifestyle interventions showed that dieting was the most effective 
way to reduce body weight excess, endocrinological and metabolic disturbances. Exercise 
alone was less effective but was superior to reduce upper body fat and maintain lean body 
mass. The combination of diet and exercise was too pressing for many women to pursue the 
intervention program in full. However, the three lifestyle interventions were equally 
effective in normalization of menstrual pattern and ovulation. Furthermore, there was an 
amelioration of the biomarkers of hyperandrogenism primarily in the diet group. Metabolic 
biomarkers including HOMA index, total cholesterol and LDL also improved in this group. 
The strongest factor to predict a reduction of BMI was increased fiber intake, while a 
decrease in trans fatty acid intake predicted reduced insulinogenic index.  
Conclusion: Dietary management and exercise, alone or in combination, are equally 
effective in improving reproductive function in overweight/obese women with PCOS. 
However, diet alone was more effective than the other interventions to improve the general 
metabolic disturbances. Increased fiber and reduced trans fatty acids intake are primary 
predictors of metabolic improvement and weight control. 
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1 INTRODUCTION 
 
Polycystic ovary syndrome (PCOS) affects about 10% of women of fertile age and is one of 
the most common causes of impaired fertility. It is characterized by oligo- or anovulation, 
hyperandrogenism (clinical and/or biochemical) and polycystic ovaries (PCO) (Azziz et al 
2016, Rosenfield and Ehrmann 2016). The syndrome was first described in 1935 by Stein 
and Leventhal (Stein and Leventhal 1935) presenting seven women with amenorrhea, 
hirsutism and polycystic ovarian morphology (PCO) (Figure 1). Initially, the syndrome was 
named after these authors and was called the Stein-Leventhal syndrome. Besides the 
abovementioned clinical features, PCOS is associated with insulin resistance, accumulation 
of abdominal fat, and obesity (BMI > 30 kg/m2) in 50% of the cases (Diamanti-Kandarakis 
and Dunaif 2012, Lim et al 2012). The metabolic long-term consequences are increased risk 
of developing type 2 diabetes mellitus, cardiovascular disease and dyslipidemia, i.e. the 
complete metabolic syndrome (Dumesic et al 2015, Gilbert et al 2018). The syndrome is 
recognized as having major impact on the reproductive and metabolic health of women 
throughout life. 
 
 
Figure 1. Clinical features of PCOS. 
 
1.1 DIAGNOSTIC CRITERIA OF PCOS 
PCOS is a heterogeneous disorder, presenting a spectrum of symptoms and manifestations 
that vary over time but also between individuals. This creates problems to diagnose and 
evaluate the syndrome. The diagnostic criteria of PCOS were first introduced in 1990 by 
experts from the National Institutes of Health (NIH) in USA (Table 1). The syndrome was 
defined as clinical and/or biochemical hyperandrogenism in combination with 
oligo/anovulation. In 2003, the diagnostic criteria for PCOS were revised at an International 
Expert Conference in Rotterdam (The Rotterdam consensus 2004) including also the 
ultrasound picture of PCO as an important feature. According to Rotterdam criteria, the 
diagnosis of PCOS includes at least two of the three following features; oligo/anovulation, 
hyperandrogenism and PCO after exclusion of secondary causes e.g. congenital adrenal 
hyperplasia (CAH), Cushing’s syndrome, acromegaly, and virilizing tumors. Consequently, 
this definition expands the population of women fulfilling the criteria of PCOS since 
various combinations of the three criteria are possible. In 2006, the Androgen Excess and 
PCOS (AE-PCOS) Society recommended that PCOS should be considered a disorder of 
hyperandrogenism and that the original NIH criteria should be accepted with some 
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modifications (Azziz et al 2006). In 2012, an Evidence-Based Methodology PCOS 
Workshop by NIH recommended the use of the broader Rotterdam criteria but with 
inclusion of a description of the specific PCOS phenotype. However, in recent international 
guidelines, the criteria of the Rotterdam consensus of 2003 were considered the best 
evidence-based diagnostic criteria (Teede et al 2018). 
 
Table 1. Different diagnostic criteria of PCOS over time. 
 NIH 1990 Rotterdam 2003 AE-PCOS 2006 NIH 2012 
extension of 
Rotterdam 
Criteria 1. HA 1. HA 1. HA 1. HA 
 2. OA 2. OA 2. OA and/or 
PCO 
2. OA 
  3. PCO  3. PCO 
Requirements Two of two 
criteria required 
Two of three 
criteria required 
Two of two 
criteria required 
Two of three 
criteria required 
and identification 
of specific 
phenotype 
Possible 
phenotypes 
A: HA + OA A: HA + OA + 
PCO  
A: HA + OA A: HA + OA + 
PCO 
  B: HA + OA B: HA + PCO B: HA + OA 
  C: HA + PCO C: HA + OA + 
PCO 
C: HA + PCO 
  D: OA + PCO  D: OA + PCO 
HA, hyperandrogenism; OA, oligo-/anovulation; PCO, polycystic ovary morphology on ultrasound 
 
1.2 EPIDEMIOLOGY 
PCOS is probably the most common endocrine disorder in women of fertile age. However, 
the prevalence is uncertain and varies depending on the diagnostic criteria that have been 
used. With the initial NIH criteria, the prevalence was reported to be 6-10 percent, while 
the Rotterdam criteria, which have extended the definition, give a prevalence of 15-20 
percent in the same population (Yildiz et al 2012). Furthermore, the incidence of PCOS 
appears to vary in different populations, and high prevalence has been reported in ethnic 
groups of Mexican, Indian and Aboriginal origins, while the prevalence in China is 
relatively low (Dumesic et al 2015). 
1.3 ETIOLOGY  
The etiology of PCOS is largely unknown. However, several etiological factors have been 
proposed including genetic causes, androgen programming in utero, as well as 
environmental factors (Norman et al 2007). Twin studies and increased familial occurrence 
of PCOS speak for a hereditary component of the syndrome, but no single genetic defect 
has been detected and therefore it is more likely that it is a polygenetic disorder (Vink et al 
2005). Experimental animal models also indicate that the hormonal environment during 
fetal life may predispose for later development of PCOS (Abbott et al 2004). In humans, 
this can be supported by the fact that diseases such as congenital adrenal hyperplasia 
(CAH), which involve increased androgen production from the adrenals during fetal life, 
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are associated with PCOS (Hague et al 1990). Furthermore, weight gain and obesity seem 
to be of great importance for the development of PCOS (Hirschberg 2009).  
1.4 PATHOPHYSIOLOGY   
Hyperandrogenism and insulin resistance are the two most important factors that can 
explain the various symptoms of PCOS. There is evidence of increased androgen 
production and release by the theca cells of the ovaries (Rosenfield and Ehrmann 2016). 
The ovarian androgen excess is augmented by disordered feedback control of pulsatile 
gonadotropin-releasing hormone (GnRH) secretion in the hypothalamus, resulting in 
stimulated luteinizing hormone (LH) secretion from the anterior pituitary and a relative 
follicle-stimulating hormone (FSH) deficiency, which will favor androgen synthesis 
(Rosenfield and Ehrmann 2016). Enhanced production of androgens will impair follicular 
development and increase the degree of follicular atresia leading to an elevated number of 
small follicles and enlarged stroma of the ovary. The clinical consequences of 
hyperandrogenism are the typical polycystic ovarian morphology (Figure 2), anovulation 
causing menstrual disorders, reduced fertility, and hirsutism and acne vulgaris (Dumesic et 
al 2015, Azziz et al 2016, Rosenfield and Ehrmann 2016). 
 
 
 
Figure 2. Ultrasound picture of a typical enlarged polycystic ovary with an increased number of 
small follicles. 
 
Women with PCOS also have an increased occurrence of insulin resistance, independent of 
obesity, leading to secondary hyperinsulinemia. The molecular mechanism seems to be a 
post-receptor defect in insulin signaling due to increased insulin receptor substrate-1 serine 
phosphorylation that selectively affects metabolic but not mitogenic pathways in muscle, 
fat tissue and in the ovary (Diamanti-Kandarakis and Duanif 2012). Hypersecretion of 
insulin directly or synergistically with LH stimulates androgen production from the ovarian 
theca cells. Furthermore, insulin inhibits the hepatic synthesis of sex hormone-binding 
globulin (SHBG) and insulin-like growth factor binding protein 1 (IGFBP-1), and thereby 
increases free and bioavailable testosterone and insulin-like growth factor (IGF) 
concentration in the ovary. Thus, hyperinsulinemia contributes to hyperandrogenism and 
ovarian dysfunction in women with PCOS (Table 2). Insulin resistance may cause 
metabolic symptoms including abdominal obesity that predisposes to type 2 diabetes, 
hypertension, hyperlipidemia and cardiovascular disease (Diamanti-Kandarakis and Duanif 
2012, Dumesic et al 2015, Azziz et al 2016).   
Testosterone may in turn induce insulin resistance by facilitating catecholamine-stimulated 
lipolysis in visceral fat tissue, thus exposing the liver to a high flux of free fatty acids, 
which could result in hepatic insulin resistance (Ek et al 2002). Furthermore, increased 
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testosterone could cause insulin resistance by inducing decreased capillary density in 
peripheral muscle tissue, as well as visceral fat accumulation as demonstrated by 
testosterone treatment in women (Hirschberg 2009). It is still unclear, whether 
hyperandrogenism or insulin resistance is the primary defect in PCOS or if combination of 
both factors is necessary for the development of the syndrome. 
 
 
Table 2. Effects of insulin that contribute to hyperandrogenism in women. 
Tissue system Effects of insulin 
Liver Inhibits SHBG synthesis 
Liver, ovary Inhibits IGFBP-1 synthesis 
Ovary Directly stimulates androgen synthesis 
Ovary Stimulates androgen synthesis by acting synergistically with LH 
Ovary Stimulates ovarian growth and cyst formation by acting synergistically with 
LH 
Ovary Up-regulates LH receptors 
Peripheral 
circulation 
Increases biologically active testosterone by stimulating ovarian 
testosterone and inhibiting hepatic SHBG synthesis 
 
1.5 REPRODUCTIVE DYSFUNCTION 
1.5.1 Impaired fertility  
PCOS is the most common cause of anovulatory infertility, being responsible for about 
70% of the cases (Broekmans et al 2006). Increased ovarian androgen production stimulates 
the initiation of primordial follicles and small antral follicles to growth. LH hypersecretion 
amplifies androgen production by the theca cells, resulting in increased follicular activation. 
However, then further follicular growth is arrested (Azziz et al 2016, Rosenfield and 
Ehrmann 2016). This could be explained by decreased levels of FSH, which are not high 
enough to stimulate full follicular maturation and selection of the dominant follicle. 
Androgen excess also initiates premature luteinization of granulosa cells, which inhibits a 
dominant follicle to develop. Increased insulin could contribute to inhibition of follicular 
development by potentiating LH-induced androgen synthesis (Azziz et al 2016, Rosenfield 
and Ehrmann 2016). Together these abnormalities will eventually result in anovulation and 
retrieval of follicles.  
There is also increasing evidence that the endocrine and metabolic abnormalities that are 
present in PCOS may have complex effects on the endometrium. Thus, higher frequency of 
implantation failure and miscarriage has been reported in PCOS (Bahri Khomami et al 
2019), indicating the importance of endometrial factors for reproductive dysfunction in 
PCOS. It is still debated whether PCOS is an independent risk factor for miscarriage or if it 
is explained by obesity (Bahri Khomami et al 2019). The endocrine conditions in PCOS 
including unopposed estrogen, hyperandrogenism and hyperinsulinemia, may negatively 
affect the endometrium and constitute a part of the infertility. Moreover, reduced oocyte 
and embryo quality have been related to PCOS (Lai et al 2018).    
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All sequelae of PCOS, including infertility, are aggravated by obesity, especially of the 
abdominal type (Hirschberg 2009). Thus, in PCOS women, obesity is associated with more 
frequent anovulation and increased frequency of infertility and moreover with a lower 
responsiveness to ovulation induction and a reduced pregnancy rate following treatment 
(Joham et al 2016). There are also reports on a lower embryo quality and a reduced 
implantation rate following in vitro fertilization (IVF) treatment in obese PCOS patients 
compared with those who are lean. Obesity in PCOS has furthermore been associated with 
a greater risk of miscarriage than normal weight women with PCOS (Hirschberg 2009). 
This has been ascribed to disturbances in fibrinolytic factors, related to both obesity and 
PCOS, which may in turn cause placental thrombosis and subsequent fetal loss.   
1.5.2 Pregnancy outcome 
Besides difficulties to become pregnant for women with PCOS, the syndrome is associated 
with significant implications for pregnancy and neonatal outcomes. Systematic reviews and 
meta-analyses have demonstrated a 3-fold increased risk of gestational diabetes in PCOS, 
and a 3 to 4-fold increased risk of pregnancy-induced hypertension and preeclampsia. 
These risks in pregnant women with PCOS have been attributed to hyperandrogenism but 
could be exacerbated by insulin resistance and obesity (Hirschberg 2009, Roos et al 2011). 
However, the specific mechanisms involved remain to be elucidated. Furthermore, a 2-fold 
higher risk of preterm delivery has been reported and increased risk of neonatal intensive 
care of the children (Palomba et al 2015).  
1.6 OBESITY AND DISTURBED APPETITE REGULATION  
The estimated prevalence of obesity in women with PCOS is 50% according to a systematic 
review (Lim et al 2012), and when adding overweight (BMI >25) the prevalence increases 
to 61%. Abdominal fat is particularly characteristic of PCOS and this clinical feature, 
which is dependent on hyperandrogenism, has a prevalence of 54% (Lim et al 2012).  
Weight gain often precedes the development of PCOS. However, there is no evidence that 
obesity causes the syndrome. Increased weight will result in insulin resistance and 
compensatory hyperinsulinemia which may induce a vicious circle of endocrine and 
metabolic abnormalities and aggravating clinical symptoms including hirsutism, sub-
fertility, and metabolic complications (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Vicious circle of endocrine and metabolic abnormalities and aggravating clinical 
symptoms of PCOS. 
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On the other hand, decreased weight is associated with resolution of PCOS symptoms. 
However, despite struggling to control their body weight many women with PCOS fail to 
maintain normal weight and gradually develop obesity. This could partly be explained by 
disturbed appetite regulation in these women.  
Many women with PCOS suffer from cravings of carbohydrates and reduced feelings of 
satiety (Hirschberg et al 2004). Furthermore, there is an association between PCOS and 
binge-eating/bulimic behavior (Cesta et al 2016). It has been demonstrated that women with 
PCOS have altered secretion of appetite regulating hormones, including the satiety 
hormone cholecystokinin and the appetite-stimulating hormone ghrelin (Hirschberg et al 
2004, Moran et al 2004). Thus, there is evidence of disturbed appetite regulation in women 
with PCOS. Increased appetite may be part of an anabolic constitution that predisposes an 
individual to obesity. However, whether this is a primary defect in PCOS or not is not 
known. 
1.7 LONG-TERM MEDICAL COMPLICATIONS 
1.7.1 Type 2 diabetes 
It is well-known that PCOS is associated with insulin resistance independent of obesity. 
The prevalence of insulin resistance has been reported to range from 44% to 70% 
depending on the criteria used (Diamanti-Kandarakis and Dunaif 2012). The insulin 
resistance in PCOS has been demonstrated in classic insulin target tissues such as muscle, 
adipose tissue and the liver, but also in the ovary (Diamanti-Kandarakis and Dunaif 2012). 
It can be selective and affect only metabolic but not mitogenic action of insulin (Bajaj and 
DeFronzo 2003, Diamanti-Kandarakis and Dunaif 2012). A relative insulin resistance leads 
to a compensatory increase in insulin secretion from the pancreatic ß-cells, and thus to 
hyperinsulinemia. 
As a consequence of insulin resistance and hyperinsulinemia, women with PCOS have an 
increased risk of type 2 diabetes. In U.S. populations of women with PCOS, it has been 
demonstrated that up to 40% have impaired glucose tolerance and 10% develop type 2 
diabetes by their fourth decade (Ehrmann et al 1999). The risk of these complications is 
higher in obese women with PCOS but also lean women have increased rates of impaired 
glucose tolerance and type 2 diabetes (Legro et al 1999). However, in European populations 
the prevalence rates appear to be lower (Gambineri et al 2004). A meta-analysis of 30 BMI-
matched studies reported increased odds ratios (OR) for both impaired glucose tolerance 
(2.54, 95% CI 1.44-4.47) and type 2 diabetes (4.00, 90% CI 1.97-8.10) (Moran et al 2010). 
Today it is well accepted that PCOS should be regarded as a prediabetic condition. 
1.7.2 Cardiovascular disease 
It is acknowledged that women with PCOS have increased prevalence of risk factors for 
cardiovascular disease such as hypertension, hyperlipidemia, abdominal obesity and 
impaired glucose tolerance or type 2 diabetes (Lim et al 2012, Gilbert el 2018). 
Furthermore, it has been demonstrated that they have increased left ventricular mass, 
endothelial dysfunction and arterial stiffness in higher frequency (Calderon-Margalit et al 
2014, Usselman et al 2019). Several of these risk factors are not fully explained by 
increased body weight in women with PCOS compared to non-PCOS women. However, 
the overall risk of cardiovascular disease in PCOS is controversial. Meta-analysis showed 
no statistical difference between PCOS and control groups in terms of myocardial 
infarction, stroke and cardiovascular mortality (deGroot et al 2011). Thus, it is yet to be 
demonstrated that elevated cardiovascular risk factors in PCOS convert to cardiovascular 
disease in the longer term. 
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1.7.3 Endometrial cancer 
Three meta-analyses have reported increased risk of endometrial cancer in PCOS 
(Chittenden et al 2009, Haoula et al 2012, Barry et al 2014). The risk of endometrial cancer 
has been shown to be 2- to 6-fold higher in women with PCOS than the general population. 
However, the association is complex with many potential confounders including obesity, 
infertility and metabolic disorders, as well as treatment in PCOS. Where BMI was 
considered, associations with PCOS and endometrial cancer are less clear (Harris and Terry 
2016). The increased risk of endometrial cancer could be explained by unopposed estrogen 
stimulation of the endometrium during anovulation and lack of protection by progesterone.  
1.8 TREATMENT 
1.8.1 Surgery 
Historically, PCOS was surgically treated with wedge resection of the ovaries by 
laparotomy (Stein 1964). This method was shown to be effective in terms of resumption of 
menses and fertility. A follow-up study in 149 patients 15-25 years after ovarian wedge 
resection demonstrated that regular menstruation pattern lasted in 88% of the patients and 
the cumulative/live birth rate was 78% (Lunde et al 2001). However, wedge resection is an 
invasive method, it is costly and could be complicated by adhesions.  
Later, laparoscopic surgery (e.g. ovarian drilling) was introduced for ovulation induction in 
PCOS (Gjønnæss 1984). This method has been compared with metformin, clomiphene 
citrate, aromatase inhibitors, gonadotrophins and combinations of these treatments in 
different studies (Palomba et al 2004, Hamed et al 2010). All together it can be concluded 
that there is no evidence of inferiority for laparoscopic surgery over other ovulation 
induction agents. However, it is an invasive surgical intervention with a small risk of 
reduced ovarian reserve and adhesion formation. Laparoscopic ovarian surgery is therefore 
recommended as second line therapy for women with PCOS and infertility and who are 
resistant to clomiphene citrate or aromatase inhibitors.  
In women with PCOS and severe obesity, bariatric surgery has been demonstrated to be 
highly effective, resulting in sustained weight loss, resolution of PCOS symptoms and 
improved fertility (Butterworth et al 2016). However, there is still controversy around 
efficacy for fertility and pregnancy outcome and bariatric surgery may adversely affect 
maternal and neonatal health (Johansson et al 2015). Perinatal risks include small for 
gestational age, premature delivery, and possibly increased infant mortality. It is 
recommended to avoid pregnancy for at least 12 months after bariatric surgery. 
1.8.2 Combined oral contraceptives 
Oral contraceptives containing both estrogen and synthetic progesterone (progestin) are 
used by many women for birth control, as well as for medical treatment of dysmenorrhea, 
heavy bleeding, endometriosis and menstrual disorders. The treatment is generally well 
tolerated with few side-effects. However, there is a small risk for venous thromboembolic 
events, which must be considered particularly in obese women (Sitruk-Ware 2016).  
Today, combined oral contraceptives (COCs) are recommended as first line 
pharmacological treatment for management of clinical symptoms in women with PCOS 
without current pregnancy wish (Teede et al 2018). COCs will regulate the menstrual cycle 
and counteract the risk of endometrial pathology due to anovulation. Furthermore, COCs 
could be used to address symptoms of hyperandrogenism like hirsutism and acne. COCs 
reduce hyperandrogenism by several mechanisms including increased binding of circulating 
testosterone to SHBG, decrease ovarian production and secretion of testosterone and 
furthermore, the progestin component can have antiandrogenic properties (De Leo et al 
2016).   
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Different combinations of COCs are available with varying pharmacological and clinical 
properties. In general, levonorgestrel-containing COCs are recommended as first choice 
due to the lowest relative risk of venous thrombosis (Sitruk-Ware 2016). On the other hand, 
third and fourth generations COCs with other progestins are more estrogen dominant and 
would therefore be preferable for women with PCOS. However, there is no scientific 
evidence that a specific formulation of COCs is more beneficial in PCOS than other 
alternatives. Various COCs have similar efficacy in treating hirsutism (Amiri et al 2018). It 
is therefore recommended to follow general guidelines when considering COC in women 
with PCOS (Teede et al 2018).  
1.8.3 Metformin 
Metformin is a biguanide that inhibits the production of hepatic glucose, and thereby 
decreases insulin secretion and increases glucose uptake in peripheral tissues (Wang YW et 
al 2017). It is a safe and low-cost medication, which has been extensively used for 
treatment of type 2 diabetes for several decades and is also used for management of 
hormonal and clinical PCOS features. However, dose dependent gastrointestinal side 
effects are common and affect compliance of the treatment. These side effects could be 
reduced by starting at a low dose and by increasing the dose gradually. Furthermore, it 
should be considered that long term use of metformin could result in low vitamin B12 
levels. 
There is evidence that metformin is beneficial to prevent weight gain, lower testosterone 
and improve metabolic features in PCOS (Teede et al 2018). However, metformin has no 
significant effect on hirsutism or protective associations with endometrial cancer (van 
Zuuren et al 2015). The beneficial effects are in general greater in overweight subgroups of 
PCOS than in lean women. Metformin could be recommended in addition to lifestyle 
changes for the treatment of weight, hormonal, and metabolic outcomes in PCOS (Hoeger 
et al 2008). The treatment may also offer greater benefit in high metabolic risk groups 
including those with diabetes risk factors, impaired glucose tolerance or high-risk ethnic 
groups, such as South East Asians, indigenous Australians and Africans. Metformin could 
as well be used to improve fertility but often in combination with other more effective 
ovulation induction agents, see below.  
1.8.4 Fertility treatments  
In women with anovulatory infertility, oral ovulation induction with letrozole is first-line 
pharmacological treatment (Wang R et al 2017). Letrozole is an aromatase inhibitor, which 
inhibits the conversion of androgens to estrogens. A daily dose of letrozole for five days in 
a row, will lead to a secondary release of LH and FSH, stimulating ovarian follicle 
development and maturation (Franik et al 2018). Clomiphene and metformin also have a 
role in ovulation induction, alone or in combination, but are less effective than letrozole to 
improve ovulation, pregnancy and live birth rate.  
Second line of pharmacological treatment is subcutaneous injection of gonadotrophins to 
stimulate ovulation (Teede et al 2018). There are several considerations to make by this 
treatment including requirement of intensive ultrasound monitoring and risk of multiple 
pregnancy. Low dose gonadotrophin protocols are recommended to optimize 
monofollicular development. If the patient does not conceive by these strategies, in vitro 
fertilization (IVF) can be offered to women with PCOS and anovulatory infertility. 
1.8.1 Lifestyle modification therapy 
Lifestyle intervention including any combination of exercise, diet and behavioral 
modification intervention is the recommended first line treatment for overweight and obese 
women with PCOS (Teede et al 2018). Several studies have demonstrated that even a 5-
10% loss in body weight loss can restore menstrual cyclicity and ovulation (Kiddy et al 
  9 
1992, Huber-Buchholz et al 1999, Clark et al 1995, Crosignani et al 2003, Moran et al 
2003, Hoeger et al 2004, Tolino et al 2005, Palomba et al 2008, Thomson et al 2008). The 
effects of different types of diets on the endocrine and metabolic parameters in PCOS have 
been compared in small randomized studies (Moran et al 2003, Stamets et al 2004). No diet 
seems to be clearly favorable over other diets with regard to the improvement of insulin 
sensitivity, weight reduction and maintenance of weight loss in PCOS patients (Moran et al 
2003, Stamets et al 2004). Exercise as single intervention has also been shown to improve 
fertility, insulin sensitivity and cardiopulmonary functional capacity in PCOS women 
(Palomba et al 2008; Vigorito et al 2007). However, whether diet or exercise is the most 
effective therapy is not known.  
Even though weight loss therapy may be successful initially, these programs do not take 
into account the problem of continued weight maintenance over forthcoming years, 
probably due to the low retention of changes in lifestyle (Anderson et al 2001). Because of 
poor compliance there is a need for different approaches to lifestyle intervention in women 
with PCOS. Structured lifestyle management with long-term support may improve patients’ 
compliance. It is also important with realistic lifestyle goals. Healthy lifestyle may be 
beneficial for health and quality of life also in the absence of weight loss. 
Our hypothesis was that weight reduction as brought about with diet, physical exercise or 
combination of both should normalize menstrual function and increase the number of 
ovulatory cycles in order to optimize fertility. We also hypothesized that dietary 
management and/or physical exercise should improve metabolic homeostasis and body 
composition in relation to dietary intake and composition.  
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2 AIMS OF THE THESIS 
 
The overall aim of the present thesis was to study effects of a 4-month intervention of 
dietary management, physical exercise or the combination of both, in a randomized design, 
on hormonal, reproductive and metabolic outcomes in overweigh/obese women with 
PCOS.  
 
Specific aims: 
 
 To compare the effects of professional supportive dietary and/or physical exercise 
intervention on hormone levels, menstrual regularity and ovarian function.  
 
 To evaluate the effects of these three different lifestyle interventions on metabolic 
outcome variables in relation to changes in food intake and dietary components in 
overweigh/obese women with PCOS.  
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3 MATERIALS AND METHODS  
3.1 SUBJECTS 
The study was performed between January 2003 and December 2008 at the Women’s 
Health Research Unit, Karolinska University Hospital, Stockholm, Sweden. Potential 
study participants were recruited by clinical referral or advertisement in the local 
newspaper and initially screened by a nurse employing a standardized telephone 
questionnaire, after which those who seemed eligible were scheduled for a visit to a 
gynecologist. Eighty-four women were screened in this manner (Figure 4), and 57 
fulfilled the inclusion criteria: a diagnosis of PCOS including all three criteria 
according to the Rotterdam Consensus (i.e., oligo-or anovulation, hyperandrogenism, 
and PCO on ultrasound) (Rotterdam, 2004); age 18-40 years; BMI > 27 kg/m2; 
absence of hormonal treatment for the last three months; no pregnancy, lactation or 
change in weight during the past year. Furthermore, they did not have any of the 
exclusion criteria: the presence of other disease or another endocrine disorder; eating 
disorder; smoking; or continuous medication including insulin sensitizing drugs. 
The study was approved by the Ethics Committee at Karolinska University Hospital 
(IRB 02-243), and the clinical trial registry number was ISRCTN48342048. Written 
informed consent was obtained from each participant. 
 
 
 
Figure 4. Study design. 
3.2 EXPERIMENTAL DESIGN AND INTERVENTIONS 
The study was designed as a Randomized Clinical Trial (RCT), in which the 57 
women were randomized to three different interventions: a) dietary management, b) 
exercise or c) combined diet and exercise (Figure 4). The randomization was carried 
out with the permuted-block randomization method using ten blocks and a block size 
of six. 
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The interventions lasted for four months with monthly visits. A follow-up visit was 
scheduled at least one year after termination of the interventions. Those who did not 
respond were reminded by another letter, followed by a telephone call. 
3.2.1 Diet 
The diet program was designed individually under the close supervision of a dietician. 
It was recommended that total daily caloric intake be reduced by at least 600 kcal/day 
in comparison with meals before the intervention, while maintaining a well-balanced 
diet containing 55-60% carbohydrates, 25-30% fat (10% saturated) and 10-15% 
proteins, according to Swedish nutritional recommendations (SNO) in 2005 (Enghardt 
et al 2005). The goal was to reduce at least 5% of body weight. A strict schedule of 
three main meals and two or three snacks was also introduced. Food intake was 
assessed by self-reporting once every 24 hours during the 4 days both immediately 
before and after four months of treatment (three working days and one weekend day). 
The individual intake of energy and nutrients was computed using a food database 
(Dietist XP, version 3.2, Kost- och Näringsdata AB, Bromma, Sweden). Energy 
consumption of macronutrients and fiber in the diet composition was evaluated. 
3.2.2 Exercise 
The exercise program, which was individually adjusted and overseen by a 
physiotherapist, was designed to enhance both the type (endurance, aerobic and/or 
weight training depending on each of the subject’s preferences), and the level of 
physical activity. The exercise included walking (with or without poles), aerobics, 
jogging, swimming, strength training, with an exertion of moderate to vigorous, 
performed 2–3 times a week with a duration of 45–60 minutes each time during the 
intervention period. Physical activity was assessed utilizing pedometers (Yamax SW-
200 Tokyo, Japan) during the four days immediately before and at the end of the 
program.  
During both types of intervention and the combination of both, monthly follow-ups 
with the dietician and/or physiotherapist were scheduled for discussion of the goals 
achieved, as well as setting up new goals for the next month. Flow diagram of the 
study procedures is shown in Figure 5. 
 
 
 
  15 
Figure 5. Flow diagram of study procedures. 
 
3.2.3 Physical examination 
Immediately before the intervention, after four months of intervention, and at the time 
of the long-term follow-up, each patient underwent a general health control involving 
measurement of blood pressure, weight, height and waist/hip ratio (WHR), blood 
sampling, gynecological examination and determination of body composition. In a 
resting and fasting state at 8:00 AM, a blood sample was collected from a peripheral 
vein and the serum separated by centrifugation and stored at – 70C, pending analysis 
for hormones, binding proteins and glucose. Menstruating women were examined in 
early follicular phase of the menstrual cycle (cycle days 1–5), whereas women with 
amenorrhea (AM) were investigated on an arbitrary day. Amenorrhea was defined as 
no bleeding for the last three months and oligomenorrhea (OM) as periods with 
intervals exceeding six weeks and five to nine periods during the previous 12 months. 
All gynecological examinations including transvaginal ultrasound using Sonoline SI-
250 equipment (Siemens Healthcare Diagnostics, Deerfield, IL, USA) were performed 
by the same investigator (ALH). The ovarian parameters evaluated were the maximal 
number of follicles in one plane and the volumes of the largest follicle of the entire 
ovary (Goswamy et al 1983). Menstrual bleedings were recorded, and ovulation 
confirmed based on an elevation in the serum level of progesterone (>17 nmol/L) 
during the luteal phase of the menstrual cycle.  
3.2.4 Body composition 
Body composition was examined by dual-energy X-ray absorptiometry (DXA) using a 
Lunar Prodigy Advance whole-body scanner (GE Healthcare Sverige AB, Stockholm, 
Sweden) as previously described (Hagmar et al 2009). The whole-body dual-energy 
X-ray absorptiometry thus obtained was divided into regions, each of which was 
evaluated for fat tissue, lean mass, bone mass, and total and spinal bone mineral 
density according to standard criteria. The Lunar software (Lunar Software Inc., 
Portland, OR, USA) calculates the amount of fat in the trunk and legs, the boundary 
between these being defined by the line drawn from the upper margin of the iliac crest 
to the neck of the femur. The ratio of trunk/leg fat was used as an estimate of the ratio 
of upper/lower body fat. 
3.2.5 Oral glucose tolerance test 
Oral glucose tolerance test (OGTT) was performed according to standard clinical 
procedure by ingestion of 75 g glucose dissolved in 250 mL water. Blood samples 
were drawn into prechilled vacutainer tubes at 0, 30, 60, 90 and 120 min during the 
OGTT. The blood samples were centrifuged at 4ºC for 10 min, 2055g, and plasma 
aliquoted and stored at -70 ºC until assayed in the same run. 
3.2.6 Biochemical measurements 
Serum levels of steroid and protein hormones, growth factors and binding proteins 
were determined by immunoassays specified in Table 3. Serum levels of testosterone, 
estradiol and 17 hydroxy progesterone (17OHP) were determined by 
radioimmunoassay (RIA), insulin by enzyme-linked immunosorbent assay (ELISA), 
FSH, LH, SHBG, dehydroepiandrosterone sulphate (DHEAS) and IGF-I by 
chemiluminescence enzyme immunoassay (CEIA), and IGFBP-1 by 
immunoradiometric assay (IRMA). 
FSH and LH values are expressed as U/L of 2:nd International reference preparation 
(IRP) FSH 78/549 and 1:st IRP LH 68/40, respectively. Apparent free concentrations 
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of testosterone was calculated from the concentrations of total testosterone, SHBG and 
a fixed albumin value of 40 g/L according to Södergård and co-workers (Södergård et 
al 1982). The ratio between total testosterone and SHBG (testosterone/SHBG-ratio, 
“free androgen index”) was also calculated. 
Glucose was assayed utilizing the YSI 2300 STAT PlusTM Glucose & Lactate 
Analyzer (YSI Inc., Life Sciences, Yellow Springs, OH, USA). As a measure of 
insulin resistance, the Homeostasis Model of Assessment (HOMA) index was 
calculated using the formula ([fasting insulin, mIU/L] x [fasting glucose, mg/dL])/405 
(Turner et al 1979). HOMA index > 3 (HOMA-IR) is defined as insulin resistance.  
Serum levels of total cholesterol, high density lipoprotein (HDL) cholesterol and 
triglycerides (TG) were determined by enzymatic clinical routine methods (DXC 800 
Access, Beckman Coulter Inc, Fullerton, CA). Low density lipoprotein (LDL) 
cholesterol was calculated according to the Friedewald formula (Friedewald et al 
1972). High-sensitive C-reactive protein (hsCRP) was analyzed immunochemically 
with kinetic nephelometry (Beckman – Coulter Inc, Fullerton, CA). 
 
Table 3. Analytical methods for hormones, growth factors and binding proteins.  
Analyte Method Manufacturer Detection 
limit 
Within 
assay CV 
Between 
assay CV 
Testosterone RIA Siemens/DPC 0.1 nmol/L 6% 10% 
Estradiol RIA Orion 5 pmol/L 5.7% 8.4% 
17OHP RIA Orion 0.1 nmol/L 7.8% 10.0% 
Insulin ELISA DAKO 3 pmol/L 6.7% 7.5% 
FSH CEIA Immulite® 
(Siemens/DPC) 
0.1 U/L 8% 8% 
LH CEIA Immulite® 
(Siemens/DPC) 
0.7 U/L 6.0% 9% 
SHBG CEIA Immulite® 
(Siemens/DPC) 
0.2 nmol/L 6.5% 8.7% 
DHEAS CEIA Immulite® 
(Siemens/DPC) 
0.8 µmol/L 8.2% 12% 
IGF-I CEIA Immulite® 
(Siemens/DPC) 
20 µg/L 3.6% 6.6% 
IGFBP-1 IRMA DSL 0.33 µg/L 4.3% 4.4% 
Manufacturers: Beckman Coulter Inc, Fullerton, CA; DAKO A/S, Glostrup, Denmark; 
Diagnostic Systems Laboratories (DSL) Inc, Webster TEX; Orion Diagnostica Ab, Esbo, 
Finland; Siemens Medical Solutions (former Diagnostic Products (DPC) Corp.), Los Angeles, 
CA. 
 
3.2.7 Statistical analyses 
All values are presented as means, standard deviations and 95% confidence intervals 
(95% CI) or as medians and inter-quartile (IQR) ranges (P25 – P75). Employing a 
Mixed model in SAS software (Cary, NC, USA), repeated measurements of the 
different parameters taken before and after the interventions were compared. The 
factors in the model were Group (Diet, Exercise and Diet + Exercise), Time (before 
and after) and the Group x Time interaction. Intention to treat analysis (ITT), using all 
available data from the 57 women in the Mixed Model analyses, was performed for 
paper II but not for paper I. Logistic regression analysis was utilized to evaluate the 
relationship between improved menstrual pattern, as well as confirmed ovulation and 
the measurements of body composition, endocrinological, gynecological and 
metabolic parameters. Within each block of parameters stepwise logistic regression 
analyses were performed and the significant variables thus obtained then included in a 
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final stepwise logistic model. Prior to these analyses, certain of the variables were log-
transformed to compensate for their positively skewed distributions. A p-value <0.05 
was considered statistically significant.  
A power calculation revealed that 3 x 15 subjects would provide 80% power to detect 
a difference in means of BMI of 1.5 kg/m2 within the groups and a difference in means 
of at least 2.0 kg/m2 between the groups, assuming that the common standard 
deviation is 1.7, with a 0.05 two-sided significance level.  
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4 RESULTS  
 
There were no significant differences in baseline values between the three groups 
(Table 4). Among the participants, none of them had pathologically elevated fasting 
blood glucose, impaired glucose tolerance or increased serum 17OHP levels, all values 
speaking against the presence of type 2 diabetes mellitus or adrenal 21- or 11ß-
hydroxylase deficiency. However, the majority had increased HOMA index >3 
indicating insulin resistance.   
 
Table 4. Baseline characteristics of the women in the three different intervention groups. 
 Diet Exercise Diet and exercise 
n 19 19 19 
Age, y 29.9 ± 5.5 31.3 ± 4.8 31.8 ± 4.9 
BMI, kg/m2 35.4 ± 4.9 34.8 ± 5.2 38.1 ± 7.0 
LH/FSH ratio 2.1 ± 1.1 2.0 ± 1.1 2.0 ± 1.2 
Testosterone, 
ng/mL 
0.51 ± 0.22 0.44 ± 0.18 0.50 ± 0.21 
SHBG, mg/L 2.3 ± 0.8 2.4 ± 0.8 2.3 ± 0.9 
Free testosterone, 
pg/mL 
16.3 ± 7.4 13.0 ± 6.1 17.2 ± 9.0 
17OHP, ng/mLa 0.86 ± 0.20 0.93 ± 0.40 0.86 ± 0.33 
Estradiol, pg/mLa 42.4 (36.8-45.9) 40.5 (33.5-53.8) 40.4 (33.4-58.5) 
Insulin, mIU/L 16 (14-28) 14 (11-22) 19 (14-27) 
Glucose, mg/dL 86.9 ± 11.5 84.6 ± 7.2 89.9 ± 10.2 
HOMA index 3.6 (3.0-6.9) 2.9 (2.3-4.7) 4.6 (3.4-5.9) 
HOMA-IR (> 3), % 72 50 81 
IGF-I, µg/La 171 ± 45 165 ± 48 162 ± 53 
IGFBP-1, µg/La 4.2 (3.3-5.6) 5.0 (2.9-9.9) 3.1 (2.4-7.6) 
Values are mean and SD or median and IQR.  
Conversion factor to SI: Testosterone nmol/L 3.467; SHBG nmol/L approx. 10.9; Free 
testosterone pmol/L 3.467; 17OHP nmol/L 3.026; Estradiol pmol/L 3.671; Insulin pmol/L 
7.175; Glucose mmol/L 0.056.  
aBaseline data based on only subjects who completed the study. 
 
4.1 BODY COMPOSITION (PAPER I) 
Of the 57 initial women, 13 were lost to follow-up, excluded or dropped out for 
different reasons leaving a final total of 43 (Figure 4). The most common finding for 
dropping out was difficulties to participate in the combined diet and exercise program 
with limited intake of rich foods and increase in physical exercise. Other reasons for 
drop out during the 4 months’ study period were: fertility treatment (n= 2), 
hypothyroidism (n=1), and ovarian cyst (n=1). 
After intervention, the 24-hour caloric intake was significantly reduced in the diet and 
the combined groups and the number of steps per day increased significantly only in 
the exercise group when analyzed according to ITT. This resulted in reduced BMI in 
all three groups from –3% to –6% with no significant difference between the groups 
(Figure 6a). In line with this, the primary readout for the statistical power calculation, 
BMI, showed a clear decrease in the diet group and the combined diet and exercise 
group, while results were less pronounced in the exercise group. Loss of body weight 
≥5% was obtained by one third in the combined material with no difference between 
groups. The percentage of total body fat measured by DXA decreased significantly 
only in the diet group. The upper body fat, mainly reflecting the abdominal fat mass, 
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decreased significantly in the exercise group (Figure 6b), but also in the total material, 
whereas lower body fat decreased significantly in the dietary and combined groups 
(Figure 7a). Lean body mass was diminished with diet, alone or in combination with 
exercise but not in the exercise only group (Figure 7b). The change in lean body mass 
was significantly different between groups (p<0.05).  
 
 
 
 
Figure 6. Change in BMI (a) and upper body fat (b) in the three different intervention groups. 
The values presented are medians (the symbols), the inter-quartile ranges (P25 – P75, the 
boxes) and the non-outlier ranges (the whiskers). * p<0.05, *** p<0.001 compared to baseline. 
 
 
 
 
 
Figure 7. Change in lower body fat (a) and lean mass (b) in the three different intervention 
groups. The values presented are medians (the symbols), the inter-quartile ranges (P25 – P75, 
the boxes) and the non-outlier ranges (the whiskers). * p<0.05, *** p<0.001 compared to 
baseline. 
 
4.2 ENDOCRINE AND METABOLIC SERUM BIOMARKERS (PAPER I) 
Before intervention, all women had disrupted ovulatory function demonstrating either 
amenorrhea (n = 24) or oligomenorrhea (n = 33). Furthermore, they displayed typical 
hormonal changes for PCOS including high serum levels of LH, LH/FSH ratio, and 
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total testosterone (Table 5). At the same time, serum levels of SHBG were low, and 
consequently, free testosterone and the testosterone/SHBG ratio were elevated. These 
clinical and endocrine changes agree with the diagnostic criteria of PCOS.  
After the interventions, the serum levels of many sex hormones were rectified whereas 
others did not change. Estradiol and SHBG were not significantly changed (Table 5). 
Total and free testosterone decreased significantly in the diet group only, whereas 
these hormones were unchanged in the exercise and diet plus exercise regimes.  
Among the metabolic hormones, fasting insulin and glucose decreased significantly in 
the dietary group, but not in the other two groups (Table 5).  Furthermore, serum IGF-I 
and IGFBP-1 increased significantly only in the dietary group. To conclude, the 
dietary regime stands out as the most effective measure in order to improve endocrine 
and metabolic biomarkers in blood.  
 
Table 5. Changes in endocrine and metabolic serum biomarkers in the three different 
intervention groups.  
 Diet Exercise Diet and exercise 
Testosterone, 
ng/mL 
-0.14 (-0.14 to -0.06) 
* 
0.00 (-0.09 to 0.06) -0.03 (-0.12 to 0.10) 
SHBG, mg/L 0.20 (-0.06 to 0.74) 0.26 (-0.14 to 0.36) 0.32 (-0.12 to 0.10) 
Free 
testosterone, 
pg/mL 
-5.21 (-5.56 to -
1.04)** 
0.00 (-2.43 to 1.39) -0.35 (-5.73 to 1.74) 
Estradiol, 
pg/mL 
12.70 (-8.92 to 27.30) -1.35 (-11.90 to 10.54) 2.16 (-13.65 to 21.62) 
Insulin, mIU/L -1.50 (-8.50 to 0.00)* 0.00 (-2.00 to 5.00) -3.00 (-7.00 to -1.00) 
Glucose, 
mg/dL 
-3.93 (-5.72 to -1.07)* 0.71 (-5.54 to 5.18) -3.66 (-6.16 to 1.52) 
IGF-I, µg/L 10.00 (-2.00 to 
44.00)* 
-2.00 (-22.00 to 13.00) 9.65 (-11.00 to 16.50) 
IGFBP-1, µg/L 1.36 (0.37 to 2.24)* 0.17 (-1.16 to 4.32) 0.04 (-0.87 to 1.54) 
Values are median and IQR.  
Conversion factor to SI: Testosterone nmol/L 3.467; SHBG nmol/L approx. 10.9; Free 
testosterone pmol/L 3.467; Estradiol pmol/L 3.671; Insulin pmol/L 7.175; Glucose mmol/L 
0.056. * p<0.05, ** p<0.01 compared to baseline.  
 
4.3 OVARIAN FUNCTION (PAPER I) 
The functional outcome of the interventions was significantly improved menstrual 
pattern shifting from amenorrhea to oligomenorrhea/regular menstruation or from 
oligomenorrhea to regular menstruation, however, without any significant difference 
between groups.  
Figure 8 shows the frequency of amenorrhea (AM)/oligomenorrhea (OM)/regular 
menstruation (RM) before and after intervention in the three intervention groups. A 
lower level of total testosterone before intervention was the strongest factor to predict 
improvement in menstrual function independently of intervention group and weight 
loss (odds ratio (OR) 0.55, 95% CI 0.35-0.85, p<0.01, respectively). After 
intervention, testosterone levels correlated significantly with menstrual status 
(AM/OM/RM) (r = -0.34, p<0.05) (Figure 9).  
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Figure 8. Frequency of amenorrhea (AM), oligomenorrhea (OM) and regular menstruation 
(RM) before and after intervention in the three intervention groups.  
 
 
 
 
 
Figure 9. Serum levels of testosterone after intervention in women with amenorrhea (AM), 
oligomenorrhea (OM) and regular menstruation (RM). 
 
Of all women, 15 had confirmed ovulation after intervention with no difference 
between groups. Ovarian volume was not altered by any of the interventions, but the 
overall number of follicles in both the right and left ovary was significantly reduced in 
all groups (data not shown). Before intervention, less degree of menstrual disturbance 
(OM instead of AM) and a lower amount of body fat mass were the strongest 
predictors of ovulation (OR 22, 95% CI 2.35-214, p<0.01 and OR 0.99, 95% CI 0.99-
1.00, p<0.05), respectively. After intervention, an increase in IGFBP-1 and a decrease 
in total testosterone were associated with ovulation (OR 723, 95% CI 1.09-477699, 
p<0.05 and OR 1.53, 95% CI 1.06-2.20, p<0.05).   
Taken together, improvements in endocrine and metabolic values were primarily seen 
in the diet group where the largest weight loss was obtained, whereas the functional 
reproductive result of improved menstrual function and ovulation seem possible to 
achieve with either form of weight-controlling regimen independently, be it in the 
form of diet or exercise or a combination of both. 
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4.4 DIETARY INTAKE AND METABOLIC OUTCOMES (PAPER II) 
4.4.1 Daily dietary intake  
Baseline intake of calories and dietary components were similar in the groups. After 
intervention, there was a general decrease in total energy intake with no significant 
difference between groups (all groups p<0.01). However, this decrease was most 
clearly shown in the diet and combined groups. Total fat intake decreased in the diet 
and combined groups where carbohydrate intake was also reduced, but exercise alone 
had no significant effect on macronutrient intake. Protein intake did not change 
significantly in any of the groups. 
Diet and combined groups consistently reduced all forms of fat intake, whereas the fat 
reduction in the exercise group was limited to saturated and monounsaturated fats 
(Figure 10). The ingested amount of trans fatty acids was significantly reduced in both 
the diet group and in the combined group, but not at all in the exercise group. 
Consequently, there was a significant group difference in trans fatty intake (p<0.05).  
 
 
 
 
Figure 10. Changes in fat composition in the three different intervention groups.  
* p<0.05, ** p<0.01, *** p<0.001, all compared to baseline.  
 
Intake of starch and sucrose decreased significantly in the combined group and starch 
also in the diet group, whereas these components of carbohydrates were not 
significantly changed in the exercise group (Figure 11). Furthermore, fiber intake 
increased significantly in both the diet and combined groups, but not in the exercise 
group, resulting in a significant group difference in this respect (p<0.05).   
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Figure 11. Changes in carbohydrate composition in the three different intervention groups.  
* p<0.05, ** p<0.01 compared to baseline. 
  
4.4.2 Metabolic outcome variables 
Waist circumference decreased significantly in all groups (Table 6). There was a 
tendency for an overall reduction in systolic blood pressure whereas diastolic blood 
pressure was unchanged. The HOMA index decreased significantly in the diet group 
and showed a similar but not statistically significant trend in the combined group but 
not in the exercise group. The change in HOMA index differed significantly between 
groups (p<0.05). However, there were no significant changes in glucose or insulin 
responses to OGTT or insulinogenic index. In the total material, there was an overall 
decrease in hsCRP, which became significant also in the exercise group. Total 
cholesterol was significantly reduced in the diet and combined groups, but not in the 
exercise group. Similarly, LDL was reduced in the diet group but not in the other 
groups. There was a significant group difference in the change in total cholesterol and 
LDL (p<0.05, respectively).  
To conclude, the dietary regime stands out as the most effective measure in order to 
improve metabolic parameters. The strongest predictor of reduced BMI was increased 
fiber intake (-0.44, p<0.05), whereas a decrease in trans fatty acid intake predicted 
reduced insulinogenic index (0.44, p<0.01). 
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Table 6. Metabolic outcome variables in the three different intervention groups.  
Values are mean and SD or median and IQR. * p<0.05, ** p <0.01, *** p<0.001 compared to 
baseline. 
 
 
  
4.5 LONG-TERM FOLLOW-UP 
Twenty-one patients, seven in each group, came to long-term follow-up 33 (19-56) 
months after termination of the intervention. Ten women declined to come, and the 
others were not possible to reach. In comparison to baseline, the mean loss in BMI 
was 8% in the dietary group, 1% in the exercise group and 11% in the combined group 
(Table 7). In patients not using hormonal contraception, 11/17 menstruated regularly. 
 
 
Table 7. Changes from baseline in BMI and endocrine variables at long-term follow-up. 
Values are median and IQR or percentage. 
 
 
  
  
Diet 
 
Exercise 
 
Diet and exercise 
Waist 
circumference, 
cm 
103.8 ± 
13.0 
95.5 ± 
13.2*** 
103.3± 
10.9 
99.3 ± 
12.5* 
110.3 ± 
14.6 
106.6 ± 
14.6* 
Systolic blood 
pressure,  
mm Hg 
129 ± 
10.7 
128 ± 11 126 ± 10 122 ± 14 126 ± 14 123 ± 11 
Diastolic blood 
pressure,  
mm Hg 
80 ± 11 82 ± 7 81 ± 11 80 ± 11 82 ± 8 80 ± 8 
HOMA index 3.6 (3.0-
6.9) 
2.9 (2.2-
3.6)* 
2.9 (2.3-
4.7) 
3.1 (2.4-
4.5) 
4.6 (3.4-
5.9) 
3.8 (2.3-
5.0) 
Insulinogenic 
index 
46.0 
(42.3-
70.8) 
35.8 
(29.9-
69.4) 
33.8 
(25.2-
39.4) 
35.9 
(24.2-
54.0) 
35.8 
(28.0-
81.6) 
31.6 
(22.4-
54.8) 
hsCRP, mg/L 4.5 ± 6.1 3.1 ± 2.5 5.1 ± 6.8 3.8 ± 3.5* 5.0 ± 4.0 3.6 ± 2.7 
Total 
cholesterol, 
mmol/L 
4.5 ± 1.0 4.0 ± 
1.4** 
4.4 ± 0.7 4.5 ± 0.6 4.7 ± 1.1 4.3 ± 1.1* 
LDL, mmol/L 2.8 ± 0.8 2.3 ± 
0.9** 
2.6 ± 0.5 2.7 ± 0.6 2.9 ± 1.0 2.6 ± 0.9 
HDL, mmol/L 1.1 ± 0.2 1.0 ± 0.2 1.2 ± 0.3 1.2 ± 0.4 1.2 ± 0.3 1.2 ± 0.3 
Triglycerides 1.4 ± 0.7 1.4 ± 0.7 1.4 ± 0.6 1.3 ± 0.4 1.4 ± 0.5 1.2 ± 0.4 
 Diet Exercise Diet and exercise 
n 7 7 7 
BMI, kg/m2 -2.6 (-5.3 to 3.9) -0.4 (-0.8 to 1.2) -5.9 (-6.4 to -1.5) 
BMI loss, % -8 -1 -11 
Regular 
menstruation 
3/5 4/6 4/6 
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5 GENERAL DISCUSSION 
5.1 CLINICAL OUTCOMES 
This thesis shows that out of the 57 overweight/obese women fulfilling all three 
Rotterdam criteria of PCOS and that were randomized to lifestyle intervention with 
diet, exercise, or both exercise and diet, 43 women were able to fully pursue the study 
until termination. The greatest dropout rate was found in the exercise plus dieting 
group, followed by the dieting, and exercise groups. Many participants claimed that 
strenuous exercise in combination with diet was a too heavy burden on their daily life 
in order to follow the study intervention. Despite difficulties with compliance in our 
lifestyle study, there were significant changes in clinical outcomes in all intervention 
groups. 
5.1.1 Body composition 
There was an overall significant decrease in BMI by the interventions with a mean 
weight loss of -4.1% corresponding to -3.9 kg. This is in line with what has been 
reported after lifestyle intervention in similar studies of obese women with PCOS 
(Haqq et al 2015). As expected, the most pronounced weight loss was in the two diet 
groups, followed by the exercise group. The weight loss remained or even improved in 
those women who were examined at the long-term follow-up. However, it must be 
noted that the drop-out rate was high and only 21 out of 57 (37%) women came to 
long-term follow-up. Thus, at least for some individuals it seems that a lifestyle 
program could be beneficial for long-term weight maintenance.  
Body composition as examined by DXA showed that total body fat decreased 
significantly only in the diet group, whereas upper body fat, which mainly reflects the 
abdominal fat mass, decreased significantly only in the exercise group. In contrast, 
lower body fat decreased significantly in the diet and combined groups. Lean body 
mass decreased with diet, alone or in combination with exercise but not with exercise 
alone.  
Diet appears to be more efficient for losing body fat than exercise, except for the 
abdominal fat. Previous interventional studies in obese women have shown that 
exercise alone results in modest reduction in body weight but more pronounced effect 
on abdominal fat (Irwin et al 2003). The reduction in abdominal fat should be 
beneficial since there are clear associations with metabolic improvements (Dunn et al 
2014). It has been suggested that the mechanism is reduced inflammation by physical 
training (Cavicchia et al 2009). Furthermore, exercise prevents the loss of lean body 
mass secondary to dietary restriction, as seen in our study. However, considering that 
women with PCOS usually have increased amount of lean mass, the clinical 
significance of some loss of lean mass is not clear. Based on our results, no 
intervention seems to be superior than the other in terms of body composition. 
5.1.2 Endocrine and metabolic serum biomarkers 
Before intervention, endocrine and metabolic serum biomarkers were comparable 
between the three groups. The women demonstrated endocrine patterns characteristic 
of PCOS, including increased LH, LH/FSH ratio and testosterone, whereas SHBG was 
low resulting in increased testosterone/SHBG ratio and high levels of free testosterone. 
Estradiol levels were in the normal range corresponding to early follicular phase. 
Serum levels of 17OHP were normal, and thus excluding mild forms of congenital 
adrenal hyperplasia. Furthermore, the frequency of HOMA index >3 was high in all 
three groups. However, none had increased fasting blood glucose levels indicating 
type 2 diabetes. 
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After intervention, serum testosterone decreased and thereby also free testosterone but 
only significant in the diet group. Furthermore, several metabolic serum biomarkers 
improved in the diet group, including reduction in fasting glucose and insulin, and 
increase in IGF-I and IGFBP-1. However, all these variables were unchanged in the 
other intervention groups. Thus, the diet intervention was more effective in reducing 
androgen levels and improving serum metabolic markers than exercise and combined 
intervention. 
There is systematic review evidence for improvement of total testosterone, free 
androgen index and fasting insulin but not for SHBG or glucose by lifestyle 
intervention (combined diet and exercise or exercise only) in women with PCOS when 
compared to minimal treatment (Moran et al 2011, Lim et al 2019). Our results for the 
diet group are in line with these results. 
5.1.3 Ovarian function  
The connection between increased body weight in PCOS and clinical consequences 
has been studied previously resulting in a recommendation of a weight reduction of at 
least 5% to achieve an improved biochemical profile and, more importantly, 
restoration of fertility (Teede et al 2018). Weight loss through a controlled low-
calorie diet and exercise should improve anthropometric indices in the PCOS patients, 
reduce ovarian volume and follicle number and restore ovulatory cycles, allowing 
spontaneous pregnancy (Kiddy et al 1992, Crosignani et al 2003, Moran et al 2003, 
Tolino et al 2005, Palomba et al 2008, Thomson et al 2008). This has been 
recommended to be achieved by conservative treatment with sustainable weight loss 
through dietary modification and exercise (Teede et al 2018).  
In our study, the weight reduction ranged from -3% to -6% with the largest weight loss 
in the dietary intervention group. However, all three interventions were equally 
effective to normalize menstrual cycling and ovulation. Although weight loss was not 
the strongest factor predicting improvement in menstrual function and ovulation, a 
Kaplan-Meier plot demonstrated a relationship between weight reduction and 
ameliorated reproductive function in those who completed the intervention (Figure 
12). Thus, a weight loss of 5 kg resulted in improved menstrual function in 50% of the 
patients and ovulation in 33%, whereas a weight loss of 10 kg improved menstrual 
function in 75% of the patients and restored ovulation in 60%. 
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Figure 12. Kaplan-Meier plot of PCOS women showing a menstrual pattern shifting from 
amenorrhea to oligomenorrhea/regular menstruation or from oligomenorrhea to regular 
menstruation. Analysis performed by per protocol, n= 43, p<0.07.  
 
The strongest factor predicting improved menstrual function was a lower testosterone 
level before intervention, indicating that women with a milder form of 
PCOS/hyperandrogenism have a greater chance of reproductive improvement. 
Similarly, we found that less degree of menstrual disturbance before intervention 
predicted restored ovulation. After intervention, we found that a decrease in serum 
testosterone and an increase in IGFBP-1 were associated with ovulation.  
PCOS is related to low serum levels of IGFBP-1 due to inhibited production by 
increased levels of insulin in the circulation (Kelly et al 2011). A decrease in IGFBP-1 
will in turn increase free IGF-I in serum, which together with insulin can stimulate 
ovarian androgen production (Kelly et al 2011). However, low levels of IGFBP-1 
seem to be mainly determined by BMI and is unlikely the cause of ovarian 
hyperandrogenism in women with PCOS (Kelly et al 2011). Instead, IGFBP-1 is 
considered a marker of insulin sensitivity with low levels reflecting insulin resistance 
(Maddux et al 2006).  
To conclude, our data suggest that both enhanced insulin sensitivity (independently of 
weight loss) and decreased hyperandrogenism could be underlying mechanisms for 
improved reproductive function by lifestyle intervention in women with PCOS.  
5.1.4 Metabolic outcomes 
The interventions obviously had an effect not only on body weight and BMI, but also 
on metabolic outcome variables such as waist circumference, a parameter that is 
usually encountered when relating diseases to the cardiovascular risk. According to 
WHO, a waist circumference > 88 cm in women is considered an increased disease 
risk. The majority of women had increased waist circumference at baseline. This 
parameter decreased significantly in all three groups but was still increased in most 
women. In line with this, there was also an overall decrease in hsCRP, primarily in the 
exercise group, as a biochemical biomarker of cardiovascular risk. However, there was 
no significant change in systolic or diastolic blood pressure. HOMA index decreased 
only in the diet group while there was no significant improvement in glucose or insulin 
response to OGTT. Furthermore, cholesterol and LDL decreased in the diet group, 
speaking of the fact that a lowered cardiovascular risk is within reach with primarily a 
dietary intervention directed at reduced carbohydrates and fat, and increased protein 
intake. With these dietary steps, also fiber intake was increased which should be 
beneficial in a cardiovascular context. However, although women with PCOS have an 
increased prevalence of risk factors for cardiovascular disease, there is no evidence of 
increased risk of cardiovascular disease (DeGroot et al 2011). It has therefore been 
speculated that these women possess protecting factors for the development of 
cardiovascular disease. On the other hand, they have clearly an increased risk of type 2 
diabetes (Ehrmann et al 1999). 
Taken together, it seems that diet, either alone or in combination with exercise, is most 
effective to improve metabolic disturbances in overweight/obese women with PCOS. 
In comparison with our results, systematic reviews in women with PCOS lend 
evidence for decreased weight, waist circumference and waist-hip-ratio by lifestyle 
intervention (combined diet and exercise or exercise only) (Moran et al 2011, Lim et al 
2019), whereas there is no support for improvement in blood lipids and the effect on 
glucose tolerance is uncertain. Our data extend previous knowledge in the field by 
showing not only metabolic advantages, but also improved reproductive outcomes. 
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5.2 LIFESTYLE CHANGE 
5.2.1 Nutrient intake  
Changes in clinical outcomes were obtained by a recommended reduction of the 
dietary energy intake of at least 600 kcal per day in each subject in keeping with a 
rectified dietary composition of 55-60% carbohydrates, 25-30% fat (10% saturated) 
and 10-15% protein according to SNO 2005. 
Over the 4-month study period, total energy intake decreased significantly in the diet 
and combined diet and exercise groups, but not in the exercise group. In a similar 
manner, total fat ingestion was reduced in the diet and combined diet and exercise 
groups, whereas carbohydrate intake was reduced in the combined exercise and diet 
group alone. None of the groups lessened the amount of protein in meal-taking. 
Instead, the percental change in protein intake increased in all intervention groups. 
This finding was encouraging in terms of balancing the foods eaten, as dietary protein 
plays a key role in body weight regulation, partly because of its effects on appetite. 
Protein intake has a well-known and even dose-dependent satiating effect (Westerterp-
Plantenga et al 2012).  
Dietary fiber represents a wide spectrum of polysaccharides that escape digestion in 
the human gastrointestinal tract, but forms substrate for microbial metabolism. The 
term “fiber” has been widely associated with positive health outcomes, with the fiber 
content of food products being a potential basis for nutritional composition claims in 
overweight and obesity. The impact of fiber-rich foods and isolated dietary fiber on 
body weight management has been studied in PCOS. Based on clinical observations, 
Marsh and Brand-Miller (2005) stated recommendations on nutrient intake and dietary 
composition for PCOS women. In their review, a diet low in saturated fat and high 
in fiber from predominantly low-glycemic-index-carbohydrate foods was 
recommended. However, their conclusions were largely based on metabolic factors 
such as reducing insulin levels and improving insulin sensitivity as an essential part of 
management of secondary long-term risks of PCOS including type 2 diabetes, 
cardiovascular disease and certain cancers.  
In our study, fiber intake increased significantly in the two diet intervention groups but 
not in the exercise only group. We found a negative correlation between the change of 
fiber intake and change of BMI, i.e. the higher the fiber intake, the greater the loss of 
BMI. Surprisingly, with a daily increase of fiber with maximally about 20 grams, 
PCOS patients were able to reduce their BMI with about 3 kg/m2. This should be 
considered as a sizable weight loss of about 10 kg. Other authors have described 
weight control correlation with only minute additions of fiber intake of about 5 grams 
per day (Qublan et al 2007). An increase of fiber at the cost of refined carbohydrates 
also seems beneficial (Liepa et al 2008). A previous study has shown women with 
PCOS to ingest about half of the recommended amount of dietary fiber (Turner-
McGrievy et al 2015), which should be optimized to similar levels as used in our study 
to achieve weight control. However, data suggest that overweight women with PCOS-
related infertility have a poor dietary intake, particularly in terms of whole 
grains, fiber, and iron, and eating behaviors inconsistent with achieving a healthy body 
weight, as well as low scores for PCOS-related quality of life. Furthermore, 
observations from Iran (Eslamian et al 2017) indicate that low fiber intake is 
significantly associated with PCOS. These data confirm our findings of negative 
relationship between taking fiber and change in BMI.  
Our results also indicate that ingestion of trans fatty acids and insulinogenic index are 
correlated. Women with PCOS should consider maintaining a diet that is patterned 
after the type 2 diabetes diet. This diet should include high amount of fibers and low 
refined carbohydrates, as well as low amounts of trans and saturated fatty acids (Liepa 
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et al 2008). The question of which type of fatty acids that should be recommended has 
been approached in a review (Faghfoori et al 2017), where diet therapy in PCOS 
should reach specific goals such as improved insulin resistance along with metabolic 
and reproductive functions. To achieve this goal, a reduction of saturated as well 
as trans fatty acids intake was claimed. In support of this, our study shows a direct 
relationship between the ingestion of trans fatty acids and the insulinogenic index. 
Taken together, our data implies a reliable adherence to the all-over dietary 
instructions given, and with best outcome in the group with dietary instructions only. 
However, as an unwished consequence of the dietary program, lean body mass 
decreased. This finding may be due to an all-over reduced energy intake. Possible 
untoward consequences of this is presently unknown. Furthermore, even if weight 
reduction was the backbone of our study, women in the exercise group were not fully 
capable of improving their eating habits. Our data suggests that PCOS patients do have 
to be directly instructed about specific changes in their eating habits to comply with a 
healthier lifestyle which will not come by itself unless instructed so.  
Few studies have investigated specific dietary composition in lifestyle interventions 
for women with PCOS. In one clinical trial, patients were randomized to one of two 
energy-restricted diets; high protein (30% protein, 40% carbohydrate, 30% fat) or high 
carbohydrate (15% protein, 55% carbohydrate, 30% fat), both with constant fat 
content (Stamets et al 2004). Over a 1-month period, weight loss was observed but 
neither diet was superior. In another trial, an 8-week low-starch/low-
dairy diet (DASH, dietary approaches to stop hypertension) resulted in reduced waist, 
improved insulin sensitivity and reduced testosterone in women with PCOS compared 
with control diet (Asemi and Esmaillzadeh 2015). A third trial comparing a high 
protein diet with a normal protein diet showed similar changes in anthropometric 
variables and no change in metabolic outcomes (Toscani et al 2011).  
It could be concluded that energy restriction and weight loss in PCOS should improve 
ovulation, fertlity, hyperandrogenism, as well as glucose- and insulin levels, insulin 
resistance and satiety hormones, whereas diet composition should be of less 
importance (Faghfoori et al 2017). Although it is likely that diet is not the root 
of PCOS, it represents a modifiable variable with potential to improve the health and 
quality of life in women with this condition. Lifestyle intervention including diet is 
therefore recommended as first line therapy to improve metabolic and reproductive 
health in these women (Teede et al 2018). Furthermore, the use of antiobesity 
pharmacological agents (e.g. orlistat and sibutramin) and bariatric surgery has been 
studied in PCOS and may offer additional treatment options (Hirschberg et al 2009).  
5.2.2 Exercise 
Aerobic exercise of moderate intensity should improve reproductive function and 
increase insulin sensitivity, which might reduce the risk of cardiovascular disease and 
type 2 diabetes in PCOS as shown in the general population. In an earlier narrative 
review (Harrison et al 2011), exercise therapy (aerobic and/or resistance) was 
evaluated as independent treatment against a comparison group. Outcomes measured 
included reproductive measures, such as ovulation, menstrual regularity and fertility, 
as well as cardiovascular risk factors. In eight studies, over a period of 12 or 24 weeks 
with variable duration of exercise sessions, the most consistent ameliorations included 
improved ovulation, increased insulin sensitivity and weight loss (4.5–10%). All over, 
these improvements were not dependent on the type of exercise, frequency or the 
length of exercise sessions. Since the studies vary considerably in design, intensity and 
outcome measures conclusive results seem elusive.  
The exercise program we promoted was individualized by a physiotherapist in order to 
stimulate both intensity and interest of the activity at onset of intervention. It included 
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brisk walking, jogging, cycling or swimming on a moderate level performed two to 
three times a week with a duration of 45-60 minutes each time. Intermittent follow-ups 
with dietician and/or physiotherapist were scheduled for compliance both for 
achieving and learning goals, for the next month. The physical activity was monitored 
by use of pedometers for four days immediately before and four days at the end of the 
exercise alone, and diet plus exercise programs. 
The outcome of the exercise subgroup showed improved menstrual regularity to a 
similar degree as diet or combined diet and exercise although weight loss was 
minimal. Furthermore, there were improvements in metabolic outcome variables by 
exercise including decreased waist circumference and hsCRP.  
Already in 2001, Norman and co-workers in a position paper stated that treatment 
should emphasize sustainable weight loss through lifestyle modification 
including exercise, but without no firm evidence of its effectiveness. It was not until 
2008, a pilot study showed that a structured exercise training program was shown to 
be effective as compared with diet (Palomba et al 2008). The frequency of menses and 
ovulation rate was significantly higher in the exercise training group than in the diet 
group, but with no difference in cumulative pregnancy rate. In parallel to this, the 
same research group showed physical exercise to improve autonomic function and 
inflammatory pattern with reduced CRP and white blood cell count in PCOS women 
(Giallauria et al 2008). Our findings of exercise are in agreement with those.  
To date there is systematic review evidence that exercise can restore menstrual cycle 
regularity in obese anovulatory patients with PCOS independent of significant weight 
loss (Teede et al 2018). Furthermore, many review papers claim physical exercise to 
be effective for improved reproductive function by way of different endocrine 
biomarkers such as testosterone, SHBG and insulin sensitivity (Legro et al 2013, 
Hakimi and Cameron 2017), whereas few research papers have studied the complex 
interaction of exercise with fertility (Al-Eisa 2017) and pregnancy rate. In a systematic 
review and meta-analysis, Haqq et al (2014, 2015) reported that exercise alone 
improves endocrine status and biomarkers of reproductive health including 
testosterone, SHBG and hirsutism but also BMI and waist circumference in women 
with PCOS. 
Although there is scientific proof of reproductive and metabolic improvements by 
exercise in PCOS, recent evidence-based guideline recommendations concluded that 
the evidence for exercise therapy in PCOS is being of low quality (Teede et al 2018, 
Stepto et al 2019). Therefore, the recommendations were based on current evidence 
for the general population. Furthermore, there is no clear evidence of which type of 
exercise that should be most beneficial for women with PCOS. However, the majority 
of studies have utilized aerobic exercise at a moderate to vigorous intensity (Stepto et 
al 2019). 
Based on evidence in the general population and in PCOS for prevention of weight 
gain and maintenance of health, the recommendation is a minimum of 150 min/week 
of moderate intensity physical activity or 75 min/week of vigorous intensity including 
muscle-strengthening activities (Teede et al 2018, Stepto et al 2019). For modest 
weight-loss, prevention of weight-regain and greater health benefits, the 
recommendation is a minimum of 250 min/week of moderate intensity or 150 
min/week of vigorous intensity (Teede et al 2018, Stepto et al 2019). 
To summarize, employing comparable groups of diet alone, diet plus exercise, and 
exercise alone, we found all interventions equal in improving menstrual regularity and 
ovulation, whereas dieting was superior to physical exercise in achieving the 
metabolic treatments goals of this thesis. Most likely this is due to the fact that the 
energy consumption induced by exercise is outweighed by the increased appetite 
induced by physical activity (Gibbons et al 2017). 
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5.3 DIETICIAN’S CLINICAL ROLE AND CHALLENGES 
Women with PCOS may present in many ways and in different settings for a dietitian. 
The prevalence of PCOS has been estimated to about 10% not including all women 
who have an undiagnosed PCOS. A great proportion of these women will most likely 
struggle with stressful, weight control issues. Many women with PCOS describe 
problems with their appetite such as ‘craving’ sweet foods or always being hungry and 
needing to eat a lot to be satisfied (Hirschberg et al 2004). Some of these issues are 
probably biological and hormonal, some are created by a dieting and food restriction 
history and some are habits.  
Management of PCOS is not a one size fits all proposition. In our study, the women 
were of different ages, they had body image and mood concerns, and all women had 
menstrual disorders and metabolic risks. The treatment lens for PCOS is focused on 
the physiology of the syndrome (hyperandrogenism and insulin resistance), and can be 
at the cost of a woman’s lived experience of the many challenges of this condition.  
For a dietician, the Swedish Dietary Guidelines 2015 is now the basis for 
recommendations and there are also lifestyle recommendations from the international 
evidence-based guideline for PCOS (Teede et al 2018). However, advice about what 
food to eat and how to exercise according to established recommendations is not 
always helpful for women with PCOS who are sensitive for the latest diets and 
exercise plans. Different trends and attitudes about lifestyle in society are challenges 
for a dietician to offer the most effective and supportive care for clients with PCOS. 
Dietitians should strengthen a sound development of a clients’ eating behavior and 
body image, by working in the borderland of medicine, culture, social attitudes, and 
accepted beliefs about female bodies and emotions.  
Lifestyle intervention improves all symptoms of PCOS, although affecting change in 
dietary and activity habits can be difficult. Unfortunately, there is not one single 
scientifically supported dietary approach that is best for PCOS. Generally, strategies 
studied include reduced calories regardless of macronutrient content, low 
carbohydrate, low fat, or high protein (Teede et al 2018). Furthermore, the dietary 
recommendations may be altered based on the patients personalized goals and co-
morbidity risk factors. But as an initial intervention, decrease in total calories is 
recommended, especially calories from sugar-sweetened beverages, saturated fat and 
trans fatty acids. In addition, fiber intake should be increased as a starting goal.  
In terms of exercise, the intensity, duration, and type of exercise that is best for weight 
loss in women with PCOS is not clear, and again may vary based on the individual. In 
most cases, the best strategy is to understand the patient’s baseline activity and to 
guide the woman to devise a personalized strategy to increase her activity and exercise 
through a realistic approach (Stepto et al 2019). Thus, the individual’s nature of 
lifestyle changes and lack of clear strategies will hugely impact the treatment result. 
The challenge to all practitioners is to bring about improvements in their own clinics. 
This includes clinics of family medicine, internal medicine, gynecology, and 
endocrinological specialties. Such efforts take time and coordination but are sorely 
needed. To establish a multidisciplinary PCOS clinic for the purpose of patient 
education, lifestyle changes and treatment, would bring together specialists of 
gynecology, physiotherapy, and nutrition in order to provide coordinated and 
comprehensive care with set goals of therapy. This type of multidisciplinary clinic is 
increasing across the globe and offers a true patient-centered care approach (Teede et 
al 2018). 
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Goals with lifestyle intervention for women with PCOS and obesity (BMI>30) 
Normalized menstrual function and restored ovulation 
Improved metabolic profile and reduced risk of metabolic complications 
Weight reduction of at least 3% for improved menstrual function and at least 6% for improved 
metabolic profile. Normal weight may not be a realistic goal to obtain by lifestyle intervention for all 
women with obesity. 
 
Diet recommendations 
Total daily caloric intake reduced by at least 600 kcal 
Fat percentage reduced to at least 25 E%, carbohydrates 55-60 E%, and protein at least to 15 E%. 
Changes in diet composition should be focused on reduction in fat and particularly saturated fat and 
trans fatty acids. Furthermore, increase in daily fiber intake of at least 25 grams. 
 
Exercise recommendations 
For prevention of weight gain and maintenance of health: a minimum of 150 min/week of moderate 
intensity physical activity or 75 min/week of vigorous intensity including muscle-strengthening 
activities. 
For modest weight-loss, prevention of weight-regain and greater health benefits: a minimum of 250 
min/week of moderate intensity or 150 min/week of vigorous intensity including muscle-
strengthening activities.  
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6 A CRITICAL EVALUATION  
 
This thesis is based on one of the first randomized lifestyle intervention trials 
performed in overweight/obese women with PCOS. The randomization provided well 
comparable groups. However, one shortcoming with the trial is the limited number of 
participants in the three treatment arms. Although the power calculation based on 
changes in BMI revealed that 15 women in each group should be an adequate sample 
size, this may have been insufficient considering the drop-out rate.  
Another possible limitation with the study could be the selection of the women 
fulfilling all three Rotterdam criteria instead of only the two necessary criteria for 
diagnosis. Thus, our results may not be applicable for all women with PCOS but rather 
those with the most outspoken features. Furthermore, in the present trial there was no 
control group of obese women with PCOS without treatment or minimal intervention. 
Therefore, we cannot evaluate efficacy of the different interventions but compare 
changes between and within our study groups. 
The dietary recommendations in our trial was based on SNO 2005, i.e. 55-60% 
carbohydrates, 25-30% fat and 15-10% protein (Enghardt et al 2005). In 2012, the 5th 
edition of the Nordic Nutrition Recommendations (NNR) were published 
(http://norden.diva-portal.org/smash/record). According to NNR 2012, energy density 
should be decreased by improved carbohydrate quality and dietary fat quality, as well 
as by increased fiber intake. Furthermore, the salt intake should be decreased by 
reduction of processed meat and fast food. The recommended intake of macronutrients 
in energy% is about the same as previous recommendations. We believe that using the 
new recommendations would not have changed our results in a significant way. 
In view of today´s public statistics, the BMI of women has steadily increased by 2% in 
the age group 20-29 years of age, maintained in the age group 30-39 but increased by 
10% in the age group 40-49 over the period 2001-2017(www.scb.se). This speaks for 
an evolving bodyweight problem in fertile age, that seem to be as relevant to study 
today. 
Since this project started, the use of analytical methods for determination of steroid 
hormones has gradually changed from immunological methods to the today golden 
standard method of liquid chromatography tandem mass spectrometry. However, this 
was not the standard ten years ago. At the time when the testosterone assays were 
performed in our project, the method used (Diagnostic Products Coat-a-Count® 
radioimmunoassay) turned out to be the best out of ten clinical routine methods when 
compared with gas chromatography - mass spectrometry (Taieb et al 2003). As far as 
we know from the literature, there is no corresponding comparison published between 
immunoassay and methods including mass spectrometry for the estradiol assay.  
When we analyzed data in paper I we used per protocol analysis but changed to ITT 
analysis in paper II, which we found more appropriate. For some variables, this 
changed the results to be non-significant or vice versa. However, it did not change our 
main results and have therefore no impact on the overall conclusions.  
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7 CONCLUSIONS 
 
 Lifestyle interventions with diet, exercise or diet and exercise in combination 
are equally effective in improving menstrual pattern and ovulation in 
overweight/obese women with PCOS, despite only a minor weight loss in the 
exercise group. Ameloriation in markers of insulin sensitivity and reduced 
hyperandrogenism seem to be important underlying mechanisms. 
 
 The summarized effects of lifestyle interventions with diet, exercise or diet and 
exercise in combination show that dieting is the most effective and feasible 
way to control body weight excess, endocrinological and metabolic 
disturbances in overweight/obese women with PCOS. Similar effects can be 
obtained by also diet in combination with exercise but this type of intervention 
often seems to be too demanding to achieve proper treatment goals. Exercise 
alone, is less effective to achieve those endocrinological and metabolic goals. 
However, exercise is beneficial to reduce upper body fat and to maintain lean 
body mass. 
 
 The most important dietary change for overweight/obese women with PCOS is 
to reduce the total daily energy intake. However, dietary components could 
also have a significant role. We identified increased fibre intake and decreased 
trans fatty acid intake as the strongest predictors of metabolic improvements 
and reduced body weight. It seems therefore not advisable to recommend low-
carbohydrate high fat diet to these women. 
 
 Lifestyle intervention including diet and/or exercise is the first-line treatment 
for all overweight/obese women with PCOS to improve reproductive and 
metabolic health. The type of intervention should be adapted to the individual 
woman’s conditions and preferencies and the goals should be realistic and 
achievable. Health professionals should support long-term maintenance of 
healthy lifestyle behaviors in these women. 
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